NasdaqCM:GALT

Stock Analysis Report

Executive Summary

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases.

Snowflake

Fundamentals

Excellent balance sheet with weak fundamentals.

Risks

  • Galectin Therapeutics is covered by less than 3 analysts.

Share Price & News

How has Galectin Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.2%

NasdaqCM:GALT

0.4%

US Biotechs

1.2%

US Market


1 Year Return

-33.4%

NasdaqCM:GALT

-10.8%

US Biotechs

1.7%

US Market

GALT underperformed the Biotechs industry which returned -10.8% over the past year.

GALT underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

GALTIndustryMarket
7 Day-4.2%0.4%1.2%
30 Day8.4%0.3%4.9%
90 Day-2.2%1.6%3.7%
1 Year-33.4%-33.4%-10.1%-10.8%3.9%1.7%
3 Year112.4%112.4%7.3%3.6%47.2%37.7%
5 Year-31.6%-31.6%2.9%-2.0%60.0%42.4%

Price Volatility Vs. Market

How volatile is Galectin Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Galectin Therapeutics undervalued based on future cash flows and its price relative to the stock market?

4.14x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Galectin Therapeutics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Galectin Therapeutics to establish if it is available at substantial discount.


Price Based on Earnings

Galectin Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.

Galectin Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Galectin Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

Galectin Therapeutics is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Galectin Therapeutics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

-8.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Galectin Therapeutics is high growth as no revenue estimate data is available.

Galectin Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.

Unable to compare Galectin Therapeutics's revenue growth to the United States of America market average as no estimate data is available.

Unable to compare Galectin Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Galectin Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Galectin Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Galectin Therapeutics performed over the past 5 years?

1.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Galectin Therapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Galectin Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Galectin Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Galectin Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Galectin Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Galectin Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Galectin Therapeutics's financial position?


Financial Position Analysis

Galectin Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Galectin Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Galectin Therapeutics's level of debt (0%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Galectin Therapeutics's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 3.7970749178287E+18x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Galectin Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.

Galectin Therapeutics has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of -19.8% each year.


Next Steps

Dividend

What is Galectin Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Galectin Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Galectin Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Galectin Therapeutics has not reported any payouts.

Unable to verify if Galectin Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Galectin Therapeutics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Galectin Therapeutics's salary, the management and board of directors tenure and is there insider trading?

6.2yrs

Average management tenure


CEO

Harold Shlevin (69yo)

1.2yrs

Tenure

US$1,730,815

Compensation

Dr. Harold H. Shlevin, Ph.D., has been President and Chief Executive Officer at Galectin Therapeutics, Inc. since July 06, 2018. He was Chief Operating Officer and Corporate Secretary of Galectin Therapeut ...


CEO Compensation Analysis

Harold's remuneration is higher than average for companies of similar size in United States of America.

Harold's compensation has increased whilst company is loss making.


Management Age and Tenure

6.2yrs

Average Tenure

69yo

Average Age

The average tenure for the Galectin Therapeutics management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

3.4yrs

Average Tenure

72yo

Average Age

The tenure for the Galectin Therapeutics board of directors is about average.


Insider Trading

Galectin Therapeutics individual insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

SellUS$99,00009 Sep 19
Gilbert Amelio
EntityIndividual
Role
Member of the Board of Directors
Director
Shares30,000
Max PriceUS$3.30
BuyUS$4,78609 Sep 19
Kevin Freeman
EntityIndividual
Role
Vice Chairman
Vice Chairman of the Board
Shares1,290
Max PriceUS$3.71
BuyUS$32,99903 Jun 19
Ed Uihlein Family Foundation, Endowment Arm
EntityCompany
Shares7,710
Max PriceUS$4.28
BuyUS$19,999,99503 Jun 19
Richard Uihlein
EntityIndividual
Role
Chairman of the Board
Chairman
Shares4,672,896
Max PriceUS$4.28
BuyUS$10,07503 Jun 19
Jack Callicutt
EntityIndividual
Role
Chief Financial Officer
CFO & Secretary
Shares2,354
Max PriceUS$4.28
BuyUS$12,98103 Jun 19
Kary Eldred
EntityIndividual
Shares3,033
Max PriceUS$4.28
BuyUS$39,10203 Jun 19
Kevin Freeman
EntityIndividual
Role
Vice Chairman
Vice Chairman of the Board
Shares9,136
Max PriceUS$4.28
BuyUS$79,51403 Jun 19
Gilbert Omenn
EntityIndividual
Role
Member of the Board of Directors
Director
Shares18,578
Max PriceUS$4.28
BuyUS$54,99403 Jun 19
Joel Lewis
EntityIndividual
Role
Member of the Board of Directors
Director
Shares12,849
Max PriceUS$4.28
BuyUS$99,85109 Apr 19
Richard Uihlein
EntityIndividual
Role
Chairman of the Board
Chairman
Shares20,700
Max PriceUS$4.82
BuyUS$3,21408 Apr 19
Joel Lewis
EntityIndividual
Role
Member of the Board of Directors
Director
Shares667
Max PriceUS$4.82
BuyUS$100,97208 Apr 19
Richard Uihlein
EntityIndividual
Role
Chairman of the Board
Chairman
Shares21,000
Max PriceUS$4.81
BuyUS$2,36508 Apr 19
Kevin Freeman
EntityIndividual
Role
Vice Chairman
Vice Chairman of the Board
Shares500
Max PriceUS$4.73
BuyUS$6,42811 Feb 19
Kevin Freeman
EntityIndividual
Role
Vice Chairman
Vice Chairman of the Board
Shares1,500
Max PriceUS$4.29
BuyUS$4,48411 Feb 19
Joel Lewis
EntityIndividual
Role
Member of the Board of Directors
Director
Shares1,000
Max PriceUS$4.48
SellUS$150,00004 Feb 19
Gilbert Amelio
EntityIndividual
Role
Member of the Board of Directors
Director
Shares30,000
Max PriceUS$5.00
BuyUS$250,55931 Jan 19
Richard Uihlein
EntityIndividual
Role
Chairman of the Board
Chairman
Shares51,500
Max PriceUS$4.87
BuyUS$4,80530 Jan 19
Joel Lewis
EntityIndividual
Role
Member of the Board of Directors
Director
Shares1,000
Max PriceUS$4.81
BuyUS$12,20026 Sep 18
Kary Eldred
EntityIndividual
Shares2,000
Max PriceUS$6.10

Ownership Breakdown


Management Team

  • Jack Callicutt (52yo)

    CFO & Secretary

    • Tenure: 6.2yrs
    • Compensation: US$1.27m
  • Eliezer Zomer (72yo)

    Executive Vice President of Manufacturing & Product Development

    • Tenure: 19.7yrs
    • Compensation: US$134.47k
  • Harold Shlevin (69yo)

    President & CEO

    • Tenure: 1.2yrs
    • Compensation: US$1.73m
  • Robert Tritt

    General Counsel

    • Tenure: 0yrs

Board Members

  • Gil Amelio (76yo)

    Director

    • Tenure: 10.6yrs
    • Compensation: US$47.00k
  • Gilbert Omenn (77yo)

    Director

    • Tenure: 5yrs
    • Compensation: US$45.00k
  • Jim Czirr (65yo)

    Director

    • Tenure: 10.6yrs
    • Compensation: US$38.50k
  • Stephen Shulman (75yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: US$41.44k
  • Dick Uihlein (74yo)

    Chairman

    • Tenure: 1.3yrs
    • Compensation: US$35.00k
  • Marc Rubin (64yo)

    Independent Director

    • Tenure: 7.9yrs
    • Compensation: US$50.86k
  • Anatole Klyosov (72yo)

    Co-founder & Member of the Scientific Board

    • Tenure: 0yrs
    • Compensation: US$203.69k
  • Kevin Mayo

    Member of the Scientific Board

    • Tenure: 0yrs
  • Kevin Freeman (57yo)

    Vice Chairman of the Board

    • Tenure: 1.7yrs
    • Compensation: US$46.00k
  • Joel Lewis (49yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: US$55.00k

Company Information

Galectin Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Galectin Therapeutics, Inc.
  • Ticker: GALT
  • Exchange: NasdaqCM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$204.439m
  • Shares outstanding: 56.63m
  • Website: https://galectintherapeutics.com

Number of Employees


Location

  • Galectin Therapeutics, Inc.
  • 4960 Peachtree Industrial Boulevard
  • Suite 240
  • Norcross
  • Georgia
  • 30071
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GALTNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDSep 2002
PHPNDB (Deutsche Boerse AG)YesCommon StockDEEURSep 2002

Biography

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company’s lead product candidate i ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/14 23:47
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.